Menu
Search
|

Menu

Close
X

Evolus Inc EOLS.OQ (NASDAQ Stock Exchange Global Market)

20.30 USD
+0.55 (+2.78%)
As of Jul 20
chart
Previous Close 19.75
Open 19.69
Volume 343,410
3m Avg Volume 118,322
Today’s High 20.80
Today’s Low 19.67
52 Week High 39.50
52 Week Low 6.78
Shares Outstanding (mil) 23.64
Market Capitalization (mil) 466.90
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.261
FY17
0.042
FY16
-0.335
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
--
8.11
Price to Book (MRQ)
vs sector
9.23
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
31.07
17.18
LT Debt to Equity (MRQ)
vs sector
31.07
13.08
Return on Investment (TTM)
vs sector
--
13.18
Return on Equity (TTM)
vs sector
--
15.09

EXECUTIVE LEADERSHIP

Vikram Malik
Chairman of the Board, Since 2018
Salary: --
Bonus: --
David Moatazedi
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Lauren Silvernail
Chief Financial Officer, Executive Vice President - Corporate Development, Since 2018
Salary: --
Bonus: --
J. Christopher Marmo
Chief Operating Officer, Since 2016
Salary: $407,550.00
Bonus: --
Rui Avelar
Chief Medical Officer, Since 2014
Salary: $325,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

17901 von Karman Ave Ste 150
IRVINE   CA   92614-5245

Phone: +1949.2844555

Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.

SPONSORED STORIES